PXL/HO/Cir-141/2021-22 Date: 24.02.2022
Hyderabad
Dear Sir/Madam,
Dear Sir/Madam,
Subject: DGFT Notification No 56/2015-2020 dt. 24th February 2022 “Amendment in Export Policy of Remdesivir Injection and API, Amphotericin-B Injections, Enoxaparin (Formulations and API) and Intra-Venous Immunoglobulin (IVIG) (Formulation and API) - Regarding”.
We would like to bring to the notice of member companies that Pharmexcil has made representations to the Department of Commerce and DGFT with a request to relax restrictions on export of Remdesivir Injection and API, Amphotericin-B Injections, Enoxaparin (Formulations and API) and Intra-Venous Immunoglobulin (IVIG) (Formulation and API)
DGFT has positively considered our request and relaxed the restrictions and issued a notification No 56/2015-2020 on 24 February 2022 amending it as “FREE” for export of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API), Amphotericin B injections, Enoxaparin (Formulation and API) and Intra-Venous Immunoglobulin (IVIG) (Formulation and API) with immediate effect.
|
S.No
|
ITC HS Codes
|
Description
|
Existing
Policy
|
Revised Policy
|
|
207AA
|
Ex293499
Ex300490
|
Injection Remdesivir and Remdesivir
ActivePharmaceuticalIngredients API)
|
Restricted
|
Free
|
|
207AB
|
Ex30049029
Ex30049099
|
Amphotericin-BInjections
|
Restricted
|
Free
|
|
207AE
|
Ex2942 Ex3001 Ex3002
|
Enoxaparin
(Formulation andAPI)
|
Restricted
|
Free
|
|
207AF
|
Ex3002
|
Intra-Venous Immunoglobulin
(IVIG)
(FormulationandAPI)
|
Restricted
|
Free
|
Member companies are requested to kindly take note of the DGFT notification. A copy of the Notification is linkedfor your ready reference.
With Regards,
Udaya Bhaskar
Director General
Encl: DGFT Notification No 56/2015-2020 dt.24 February 2022
|
